Challenges, solutions, and recommendations for Alzheimer's disease combination therapy

详细信息    查看全文

• 作者：James A. Hendrix^a ; ^{jhendrix@alz.org" class="auth_mail" title="E-mail the corresponding author} ; Randall J. Bateman^b ; H. Robert Brashear^c ; Cynthia Duggan^b ; Maria C. Carrillo^a ; Lisa J. Bain^d ; Ronald DeMattos^e ; Russell G. Katz^f ; Susanne Ostrowitzki^g ; Eric Siemers^e ; Reisa Sperling^h ; Ottavio V. Vitoloⁱ
• 刊名：Alzheimer's & Dementia
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：12
• 期：5
• 页码：623-630
• 全文大小：681 K

文摘

Given the complex neuropathology Alzheimer's disease (AD), combination therapy may be necessary for effective treatment. However, scientific, pragmatic, regulatory, and business challenges need to be addressed before combination therapy for AD can become a reality. Leaders from academia and industry, along with a former member of the Food and Drug Administration and the Alzheimer's Association, have explored these challenges and here propose a strategy to facilitate proof-of-concept combination therapy trials in the near future. First, a more integrated understanding of the complex pathophysiology and progression of AD is needed to identify the appropriate pathways and the disease stage to target. Once drug candidates are identified, novel clinical trial designs and selection of appropriate outcome assessments will be needed to enable definition and evaluation of the appropriate dose and dosing regimen and determination of efficacy. Success in addressing this urgent problem will only be achieved through collaboration among multiple stakeholders.